Breast Cancer Liquid Biopsy Market Report

RA01603

Breast Cancer Liquid Biopsy Market, by End Use (Reference Laboratories, Hospitals and Physician Laboratories, Other End Users), Circulationg Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers): Global Opportunity Analysis and Industry Forecast, 2020-2027

RA01603

Pages: 100

Feb 2023

The global breast cancer liquid biopsy market is estimated to surpass $1,161.8 million by 2027, exhibiting a CAGR of 23.1% from 2020 to 2027.

The report aims to offer a clear picture of the current scenario and future growth of the global breast cancer liquid biopsy market. The report provides scrupulous analysis of global breast cancer liquid biopsy market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.

The report articulates the key opportunities and factors propelling the global breast cancer liquid biopsy market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porter’s five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global breast cancer liquid biopsy market. Regional market analysis of these segments is also provided in the report. The report segments the global breast cancer liquid biopsy market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the breast cancer liquid biopsy market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global breast cancer liquid biopsy market. A comprehensive summary of 10 foremost players operating in the global breast cancer liquid biopsy market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, company’s financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the global breast cancer liquid biopsy market.

RESEARCH METHODOLOGY

Research Dive has formulated the report by in-house market analysts after deeply scrutinizing the market landscape. The market estimations stated in the report have been derived using proven research methodologies and analytical models & tools. Use of such effective and advanced tools, helps market analysts to scrutinize, filter, and offer highly accurate data and estimations. The report provides an extensive research and analysis backed with numerous factual data, which mainly include industry players’ interviews, renowned and trustworthy sources of statistics, and regional intelligence. The in-depth insights entailed in the report can help investors and market players to understand investment suitability and grab opportunities for developments, partnerships, and investments in the global market.

The research report is formed by collating different statistics and information concerning the breast cancer liquid biopsy market. Long hours of deliberations and interviews have been performed with a group of investors and stakeholders, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. Numerous product type literatures, company annual reports, market publications, and other such relevant documents of the leading market players have been studied, for better & broader understanding of market penetration. Furthermore, medical journals, trustworthy industry newsletters, government websites, and trade associations’ publications have also been evaluated for extracting vital industry insights.

KEY MARKET BENEFITS

This report is a compilation of qualitative assessment by industry analysts, detailed information & study, and valid inputs from industry participants & experts across the value chain

An in-depth analysis along with recent trends of the industry are provided in the report to identify & comprehend the prevailing opportunities and the tactical assessment of the global breast cancer liquid biopsy market growth

The market size and forecasts are derived by scrutinizing market boomers and restraints, and key developments in the breast cancer liquid biopsy market

The report studies the market from 2019 to 2027 and maps the qualitative impact of several industry factors on market segments as well as geographies

The development strategies implemented by the key industry players are conscripted in the report to understand the competitive scenario of the global breast cancer liquid biopsy market

The report also offers insights into foremost market players, Porter’s Five Analysis, and top winning business strategies

KEY MARKET SEGMENTS

The global breast cancer liquid biopsy market is segmented on the basis of the following:

End Use: Reference Laboratories, Hospitals and Physician Laboratories, Other End Users

Circulationg Biomarker: Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers

Region: North America, Europe, Asia Pacific, and LAMEA

This segment is further sub-segmented into the following regions:

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA

KEY PLAYERS

The leading players stated in the report are Guardant Health, Inc. , Fluxion Biosciences, Inc. , Roche Diagnostics , Guardant Health, Inc. . The report articulates the business overview including financial and annual performance, newest strategic plans & developments, product range, and SWOT analysis of all the players mentioned in the report.

1. QIAGEN N.V.

2. Roche Diagnostics

3. Bio-Rad Laboratories

4. Myriad Genetics

5. Menarini Silicon Biosystems

6. Illumina

7. Cynvenio Biosystems, Inc.

8. Genomic Health, Inc.

9. Thermo Fisher Scientific Inc.

10. Fluxion Biosciences, Inc.

11. Biodesix, Inc.

12. Guardant Health, Inc.

13. Isogen Life Science B.V.

1. RESEARCH METHODOLOGY
- 1.1. Desk Research
- 1.2. Real time insights and validation
- 1.3. Forecast model
- 1.4. Assumptions and forecast parameters
- 1.5. Market size estimation
  - 1.5.1. Top-down approach
  - 1.5.2. Bottom-up approach
2. REPORT SCOPE
- 2.1. Market definition
- 2.2. Key objectives of the study
- 2.3. Report overview
- 2.4. Market segmentation
- 2.5. Overview of the impact of COVID-19 on Global Breast Cancer Liquid Biopsy Market
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
- 4.1. Introduction
- 4.2. Growth impact forces
  - 4.2.1. Drivers
  - 4.2.2. Restraints
  - 4.2.3. Opportunities
- 4.3. Market value chain analysis
  - 4.3.1. List of raw material suppliers
  - 4.3.2. List of manufacturers
  - 4.3.3. List of distributors
- 4.4. Innovation & sustainability matrices
  - 4.4.1. Technology matrix
  - 4.4.2. Regulatory matrix
- 4.5. Porter’s five forces analysis
  - 4.5.1. Bargaining power of suppliers
  - 4.5.2. Bargaining power of consumers
  - 4.5.3. Threat of substitutes
  - 4.5.4. Threat of new entrants
  - 4.5.5. Competitive rivalry intensity
- 4.6. PESTLE analysis
  - 4.6.1. Political
  - 4.6.2. Economical
  - 4.6.3. Social
  - 4.6.4. Technological
  - 4.6.5. Environmental
- 4.7. Impact of COVID-19 on Breast Cancer Liquid Biopsy Market
  - 4.7.1. Pre-covid market scenario
  - 4.7.2. Post-covid market scenario
5. Breast Cancer Liquid Biopsy Market, By Technology
- 5.1. Overview
- 5.2 Reference Laboratories
  - 5.2.1 Definition, key trends, growth factors, and opportunities
  - 5.2.2 Market size analysis, by region, 2020-2027
  - 5.2.3 Market share analysis, by country, 2020-2027
- 5.3 Hospitals and Physician Laboratories
  - 5.3.1 Definition, key trends, growth factors, and opportunities
  - 5.3.2 Market size analysis, by region, 2020-2027
  - 5.3.3 Market share analysis, by country, 2020-2027
- 5.4 Other End Users
  - 5.4.1 Definition, key trends, growth factors, and opportunities
  - 5.4.2 Market size analysis, by region, 2020-2027
  - 5.4.3 Market share analysis, by country, 2020-2027
- 5.5 Research Dive Exclusive Insights
  - 5.5.1 Market attractiveness
  - 5.5.2 Competition heatmap
6. Breast Cancer Liquid Biopsy Market, By Therapeutic Area
- 6.1. Overview
- 6.2 Circulating Tumor Cells (CTCs)
  - 6.2.1 Definition, key trends, growth factors, and opportunities
  - 6.2.2 Market size analysis, by region, 2020-2027
  - 6.2.3 Market share analysis, by country, 2020-2027
- 6.3 Cell-free DNA (cfDNA)
  - 6.3.1 Definition, key trends, growth factors, and opportunities
  - 6.3.2 Market size analysis, by region, 2020-2027
  - 6.3.3 Market share analysis, by country, 2020-2027
- 6.4 Extracellular Vesicles (EVs)
  - 6.4.1 Definition, key trends, growth factors, and opportunities
  - 6.4.2 Market size analysis, by region, 2020-2027
  - 6.4.3 Market share analysis, by country, 2020-2027
- 6.5 Other Circulating Biomarkers
  - 6.5.1 Definition, key trends, growth factors, and opportunities
  - 6.5.2 Market size analysis, by region, 2020-2027
  - 6.5.3 Market share analysis, by country, 2020-2027
- 6.6 Research Dive Exclusive Insights
  - 6.6.1 Market attractiveness
  - 6.6.2 Competition heatmap
7. Breast Cancer Liquid Biopsy Market, By Region
- 7.1 North America
  - 7.1.1 U.S
    - 7.1.1.1 Market size analysis, By Technology, 2020-2027
    - 7.1.1.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.1.2 Canada
    - 7.1.2.1 Market size analysis, By Technology, 2020-2027
    - 7.1.2.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.1.3 Mexico
    - 7.1.3.1 Market size analysis, By Technology, 2020-2027
    - 7.1.3.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.1.4 Research Dive Exclusive Insights
    - 7.1.4.1 Market attractiveness
    - 7.1.4.2 Competition heatmap
- 7.2 Europe
  - 7.2.1 Germany
    - 7.2.1.1 Market size analysis, By Technology, 2020-2027
    - 7.2.1.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.2.2 UK
    - 7.2.2.1 Market size analysis, By Technology, 2020-2027
    - 7.2.2.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.2.3 France
    - 7.2.3.1 Market size analysis, By Technology, 2020-2027
    - 7.2.3.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.2.4 Spain
    - 7.2.4.1 Market size analysis, By Technology, 2020-2027
    - 7.2.4.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.2.5 Italy
    - 7.2.5.1 Market size analysis, By Technology, 2020-2027
    - 7.2.5.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.2.6 Rest of Europe
    - 7.2.6.1 Market size analysis, By Technology, 2020-2027
    - 7.2.6.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.2.7 Research Dive Exclusive Insights
    - 7.2.7.1 Market attractiveness
    - 7.2.7.2 Competition heatmap
- 7.3 Asia-Pacific
  - 7.3.1 China
    - 7.3.1.1 Market size analysis, By Technology, 2020-2027
    - 7.3.1.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.3.2 Japan
    - 7.3.2.1 Market size analysis, By Technology, 2020-2027
    - 7.3.2.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.3.3 India
    - 7.3.3.1 Market size analysis, By Technology, 2020-2027
    - 7.3.3.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.3.4 Australia
    - 7.3.4.1 Market size analysis, By Technology, 2020-2027
    - 7.3.4.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.3.5 South Korea
    - 7.3.5.1 Market size analysis, By Technology, 2020-2027
    - 7.3.5.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.3.6 Rest of Asia-Pacific
    - 7.3.6.1 Market size analysis, By Technology, 2020-2027
    - 7.3.6.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.3.7 Research Dive Exclusive Insights
    - 7.3.7.1 Market attractiveness
    - 7.3.7.2 Competition heatmap
- 7.4 LAMEA
  - 7.4.1 Brazil
    - 7.4.1.1 Market size analysis, By Technology, 2020-2027
    - 7.4.1.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.4.2 Saudi Arabia
    - 7.4.2.1 Market size analysis, By Technology, 2020-2027
    - 7.4.2.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.4.3 UAE
    - 7.4.3.1 Market size analysis, By Technology, 2020-2027
    - 7.4.3.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.4.4 South Africa
    - 7.4.4.1 Market size analysis, By Technology, 2020-2027
    - 7.4.4.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.4.5 Rest of LAMEA
    - 7.4.5.1 Market size analysis, By Technology, 2020-2027
    - 7.4.5.2 Market size analysis, By Therapeutic Area, 2020-2027
  - 7.4.6 Research Dive Exclusive Insights
    - 7.4.6.1 Market attractiveness
    - 7.4.6.2 Competition heatmap
8. Competitive Landscape
- 8.1 Top winning strategies, 2020-2027
  - 8.1.1 By strategy
  - 8.1.2 By year
- 8.2 Strategic overview
- 8.3 Market share analysis, 2020-2027
9. Company Profiles
- 9.1 QIAGEN N.V.
  - 9.1.1 Overview
  - 9.1.2 Business segments
  - 9.1.3 Product portfolio
  - 9.1.4 Financial performance
  - 9.1.5 Recent developments
  - 9.1.6 SWOT analysis
- 9.2 Roche Diagnostics
  - 9.2.1 Overview
  - 9.2.2 Business segments
  - 9.2.3 Product portfolio
  - 9.2.4 Financial performance
  - 9.2.5 Recent developments
  - 9.2.6 SWOT analysis
- 9.3 Bio-Rad Laboratories
  - 9.3.1 Overview
  - 9.3.2 Business segments
  - 9.3.3 Product portfolio
  - 9.3.4 Financial performance
  - 9.3.5 Recent developments
  - 9.3.6 SWOT analysis
- 9.4 Myriad Genetics
  - 9.4.1 Overview
  - 9.4.2 Business segments
  - 9.4.3 Product portfolio
  - 9.4.4 Financial performance
  - 9.4.5 Recent developments
  - 9.4.6 SWOT analysis
- 9.5 Menarini Silicon Biosystems
  - 9.5.1 Overview
  - 9.5.2 Business segments
  - 9.5.3 Product portfolio
  - 9.5.4 Financial performance
  - 9.5.5 Recent developments
  - 9.5.6 SWOT analysis
- 9.6 Illumina
  - 9.6.1 Overview
  - 9.6.2 Business segments
  - 9.6.3 Product portfolio
  - 9.6.4 Financial performance
  - 9.6.5 Recent developments
  - 9.6.6 SWOT analysis
- 9.7 Cynvenio Biosystems, Inc.
  - 9.7.1 Overview
  - 9.7.2 Business segments
  - 9.7.3 Product portfolio
  - 9.7.4 Financial performance
  - 9.7.5 Recent developments
  - 9.7.6 SWOT analysis
- 9.8 Genomic Health, Inc.
  - 9.8.1 Overview
  - 9.8.2 Business segments
  - 9.8.3 Product portfolio
  - 9.8.4 Financial performance
  - 9.8.5 Recent developments
  - 9.8.6 SWOT analysis
- 9.9 Thermo Fisher Scientific Inc.
  - 9.9.1 Overview
  - 9.9.2 Business segments
  - 9.9.3 Product portfolio
  - 9.9.4 Financial performance
  - 9.9.5 Recent developments
  - 9.9.6 SWOT analysis
- 9.10 Fluxion Biosciences, Inc.
  - 9.10.1 Overview
  - 9.10.2 Business segments
  - 9.10.3 Product portfolio
  - 9.10.4 Financial performance
  - 9.10.5 Recent developments
  - 9.10.6 SWOT analysis
- 9.11 Biodesix, Inc.
  - 9.11.1 Overview
  - 9.11.2 Business segments
  - 9.11.3 Product portfolio
  - 9.11.4 Financial performance
  - 9.11.5 Recent developments
  - 9.11.6 SWOT analysis
- 9.12 Guardant Health, Inc.
  - 9.12.1 Overview
  - 9.12.2 Business segments
  - 9.12.3 Product portfolio
  - 9.12.4 Financial performance
  - 9.12.5 Recent developments
  - 9.12.6 SWOT analysis
- 9.13 Isogen Life Science B.V.
  - 9.13.1 Overview
  - 9.13.2 Business segments
  - 9.13.3 Product portfolio
  - 9.13.4 Financial performance
  - 9.13.5 Recent developments
  - 9.13.6 SWOT analysis

Purchase Options

Individual License $4290 Corporate License $4920

Personalize this research

Triangulate with your own data
Request your format and definition
Get a deeper dive on a specific application, geography, customer or competitor

10% Off on Customization

Speak To The Analyst
Or Schedule A Call

+ 1-888-961-4454 Toll - Free
support@researchdive.com

Breast Cancer Liquid Biopsy Market Report

1. RESEARCH METHODOLOGY

1.1. Desk Research

1.2. Real time insights and validation

1.3. Forecast model

1.4. Assumptions and forecast parameters

1.5. Market size estimation

1.5.1. Top-down approach

1.5.2. Bottom-up approach

2. REPORT SCOPE

2.1. Market definition

2.2. Key objectives of the study

2.3. Report overview

2.4. Market segmentation

2.5. Overview of the impact of COVID-19 on Global Breast Cancer Liquid Biopsy Market

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

4.1. Introduction

4.2. Growth impact forces

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunities

4.3. Market value chain analysis

4.3.1. List of raw material suppliers

4.3.2. List of manufacturers

4.3.3. List of distributors

4.4. Innovation & sustainability matrices

4.4.1. Technology matrix

4.4.2. Regulatory matrix

4.5. Porter’s five forces analysis

4.5.1. Bargaining power of suppliers

4.5.2. Bargaining power of consumers

4.5.3. Threat of substitutes

4.5.4. Threat of new entrants

4.5.5. Competitive rivalry intensity

4.6. PESTLE analysis

4.6.1. Political

4.6.2. Economical

4.6.3. Social

4.6.4. Technological

4.6.5. Environmental

4.7. Impact of COVID-19 on Breast Cancer Liquid Biopsy Market

4.7.1. Pre-covid market scenario

4.7.2. Post-covid market scenario

5. Breast Cancer Liquid Biopsy Market, By Technology

5.1. Overview

5.2 Reference Laboratories

5.2.1 Definition, key trends, growth factors, and opportunities

5.2.2 Market size analysis, by region, 2020-2027

5.2.3 Market share analysis, by country, 2020-2027

5.3 Hospitals and Physician Laboratories

5.3.1 Definition, key trends, growth factors, and opportunities

5.3.2 Market size analysis, by region, 2020-2027

5.3.3 Market share analysis, by country, 2020-2027

5.4 Other End Users

5.4.1 Definition, key trends, growth factors, and opportunities

5.4.2 Market size analysis, by region, 2020-2027

5.4.3 Market share analysis, by country, 2020-2027

5.5 Research Dive Exclusive Insights

5.5.1 Market attractiveness

5.5.2 Competition heatmap

6. Breast Cancer Liquid Biopsy Market, By Therapeutic Area

6.1. Overview

6.2 Circulating Tumor Cells (CTCs)

6.2.1 Definition, key trends, growth factors, and opportunities

6.2.2 Market size analysis, by region, 2020-2027

6.2.3 Market share analysis, by country, 2020-2027

6.3 Cell-free DNA (cfDNA)

6.3.1 Definition, key trends, growth factors, and opportunities

6.3.2 Market size analysis, by region, 2020-2027

6.3.3 Market share analysis, by country, 2020-2027

6.4 Extracellular Vesicles (EVs)

6.4.1 Definition, key trends, growth factors, and opportunities

6.4.2 Market size analysis, by region, 2020-2027

6.4.3 Market share analysis, by country, 2020-2027

6.5 Other Circulating Biomarkers

6.5.1 Definition, key trends, growth factors, and opportunities

6.5.2 Market size analysis, by region, 2020-2027

6.5.3 Market share analysis, by country, 2020-2027

6.6 Research Dive Exclusive Insights